SARASOTA, Fla., July 5 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced that members of its senior Scientific and Management Team will be exhibiting at The World Congress on Industrial Biotechnology and Bioprocessing in Toronto, Canada on July 11 - 14.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060629/FLTH021LOGO )
The World Congress on Industrial Biotechnology and Bioprocessing is the premiere gathering of thought leaders, investors, researchers and business executives in industrial biotechnology, bioenergy and bioprocessing. This industry conference will provide IBC an opportunity to showcase its proprietary and licensed technologies, including the recently announced ALCHEMx Production Platform(TM), to potential business partners, peers, investors and industry media.
Conference attendees will have the opportunity to learn how IBC’s technologies and business strategy can positively alter traditional chemical production methods, and reduce costs and environmental impact.
“Now that we have the ALCHEMx Production Platform(TM) in place, we are positioned to seek out additional partnerships and agreements with companies within the chemical industry. Many of the attendees at this conference not only represent possible IBC partners, but also end users of our technology,” said Gary Howell, IBC’s Vice President of Business Development.
“There is fast-growing need by both chemical buyers and manufactures to investigate and implement alternative production methods that lessen or even eliminate environmental impact, while at the same time reduce costs. IBC’s technology has this ability and we hope to have many positive discussions during this conference,” said Andy Badolato, CEO of IBC.
IBC will be conducting exploratory meetings with interested parties throughout the conference dates. Those interested are encouraged to contact IBC in advance of the conference to pre-set specific meeting times.
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a higher purity and with a substantially lower environmental impact than traditional methods. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC seeks to bring to market new and established chemicals that are in high demand for use in flavors and fragrances, fine chemicals, pharmaceuticals, cosmeceuticals, agricultural, biopesticides, bio-energy, biomaterials and biopolymer industries. IBC’s pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large commercial production levels. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and seeks to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable, biological-based solutions and related intellectual property patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward- looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Photo: http://www.newscom.com/cgi-bin/prnh/20060629/FLTH021LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comIndustrial Biotechnology Corporation
CONTACT: Jack Hensley, Vice President, Public & Investor Relations,Industrial Biotechnology Corporation, +1-941-925-2500, orjhensley@industrialbiotechnology.com
Web site: http://www.industrialbiotechnology.com/
